Yuyu Pharma begins subject enrolment in Phase II dry eye disease study
The Phase II clinical study will assess the efficacy, safety, and tolerability of YP-P10 to help advance DED patients’ treatment.

The Phase II clinical study will assess the efficacy, safety, and tolerability of YP-P10 to help advance DED patients’ treatment.
SKYCovione was jointly developed with the University of Washington School of Medicine’s Institute for Protein Design.
The trial evaluated rivoceranib in 80 patients, including 53 based in the US.
CP-COV03 is similar to the human efficacy test of penicillin conducted in 1941, in several ways.
The companies have submitted a BLA for SKYCovione to the Korean MFDS on obtaining positive Phase III results.
In the Phase IIb trial of S-217622 that enrolled 428 patients in Japan and South Korea, no serious safety issues…
The Phase II trial will be sponsored by Genome while MSD will supply Keytruda under the deal.
The biotech firm received approval from the Australian regulatory authority for the trial in October last year.
Thank you for subscribing to Clinical Trials Arena